Researchers are testing a medication called atezolizumab and its effects on early-stage non-small cell lung cancer (NSCLC). Atezolizumab is an experimental immunotherapy medicine, which is a man-made antibody.
Antibodies are used by the immune system to identify and destroy bacteria, viruses and tumor cells. Atezolizumab is approved to treat advanced cancer of the bladder and lung, and researchers believe it may help people who have early-stage NSCLC. In this study, participants will get either atezolizumab and chemotherapy or a placebo and chemotherapy before undergoing surgery to remove their tumor.